-

Nation’s Biggest Health Insurer Announces Requirement that Molecular and Genetic Test Claims include Z-Codes as of August 1, 2023

AUSTIN, Texas--(BUSINESS WIRE)--Clinical laboratories across the nation are scrambling to meet a looming August 1 deadline that requires them to include Z-Codes with certain molecular and genetic test claims they submit to the nation’s largest health insurer. Labs that fail to comply may experience a major disruption in cash flow after implementation of this new requirement.

Announced last month by UnitedHealthcare, effective Aug. 1, genetic test claims associated with about 250 CPT codes must include a Z-Code issued by the MolDx Diagnostic Exchange (DEX) registry, operated by Palmetto GBA, a Medicare Administrative Contractor. This announcement surprised many clinical labs and left them with only weeks to apply for the Z-Codes they need when submitting molecular test claims to UHC.

To help clinical labs meet their needs for swift Z-Code registration of their genetic tests, The Dark Report and DarkDaily are presenting a free, 90-minute webinar, “Essential Guide to Obtaining Z-Codes for Molecular and Genetic Tests” Thursday, June 29, at 1:00 PM EDT.

Keynote speaker is Gabriel Bien-Willner, MD, PhD, Chief Medical Officer of Palmetto GBA, as well as Medical Director of the Molecular Diagnostic Services Program (MolDx). He will provide an up-to-the-minute picture of the DEX MolDx Z-Code registry, including the application and documentation processes needed to register a molecular test and obtain a unique Z-Code for that test.

Second to speak is Valerie Collier, MS, CGC, Genetic Counselor at ARUP Laboratories. She has been directly involved in helping ARUP Laboratories and its clients obtain Z-Codes for their new molecular and genetic tests. Collier’s insights and recommendations are based on four years of submitting applications to DEX MolDx, responding to the documentation requirements, and receiving Z-Codes for these new genetic tests.

Next to present is Kyle Fetter, Chief Operating Officer at XiFin, Inc. Since the inception of the MolDx and Z-Code programs more than a decade ago, Fetter and his team have worked with client laboratories to help them register their molecular and genetic tests and obtain Z-Codes. Fetter’s team also interacts regularly with other private health insurers and is tracking their plans to follow UHC’s lead and issue their own requirements that molecular test claims include Z-Codes.

Full details on the speakers, content, and how to register for this valuable, free webinar are at https://www.darkdaily.com. XiFin provided an Educational Grant in support of this webinar.

For additional information, contact Amanda Curtis, 512-264-7103

About The Dark Intelligence Group

Since 1995, The Dark Intelligence Group has been the leading source of exclusive and reliable business intelligence about clinical laboratories, pathology groups, and laboratory diagnostics. The Dark Intelligence Group is the publisher of Dark Daily and The Dark Report, and each spring The Dark Intelligence Group hosts the renowned Executive War College on Diagnostics, Clinical Laboratory and Pathology Management.

Contacts

Amanda Curtis
acurtis@darkreport.com

More News From The Dark Intelligence Group

LabX Media Group Acquires The Dark Intelligence Group Inc, including The Dark Report and the Executive War College

AUSTIN, Texas--(BUSINESS WIRE)--The Dark Intelligence Group (TDIG) announced today that it has sold all its information services assets to LabX Media Group of Midland, Ontario, Canada. This sale involves all TDIG products and services, such as The Dark Report intelligence service, DarkDaily ebriefings, webinars, reports, and events, including the Executive War College on Diagnostic, Laboratory, and Pathology Management, the largest global conference on laboratory management for senior laborator...

Operationalizing FDA LDT Compliance: Expert Panel Reveals Essential Strategies and Actions for Meeting the 1st Reporting Milestone

AUSTIN, Texas--(BUSINESS WIRE)--Many clinical laboratories are now under the gun to achieve Phase One compliance with the Food and Drug Administration’s (FDA) LDT rule before the May 2025 deadline. Labs performing LDTs must take immediate action to protect their most important LDTs that improve patient care while generating substantial reimbursement. This is a high stakes situation for labs offering LDTs because they have only five months to secure their most valuable LDTs. To help labs underst...

Experts to Identify Essential Steps & Pitfalls to Help Clinical Laboratories Meet the Deadline to Comply with the FDA’s Laboratory Developed Test (LDT) Rule

AUSTIN, Texas--(BUSINESS WIRE)--With the first important deadline for compliance with the Food and Drug Administration’s (FDA) LDT rule only eight months away, experts urge clinical laboratories performing LDTs to take immediate action. This is essential to protect their most important LDTs that improve patient care while generating substantial reimbursement. The FDA’s final rule on Laboratory Developed Tests (LDTs) ushers in a radical overhaul of the FDA’s longstanding policy of enforcement di...
Back to Newsroom